Results 111 to 120 of about 5,547 (244)

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 535-544, February 2026.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source

Immunopharmacology 2020. V International Congress on Immunopharmacology

VacciMonitor, 2020
The Organizing Committee of the “V International Congress on Immunopharmacology” (Immunopharmacology 2020) organized by the Cuban Society of Pharmacology, BioCubaFarma and the International Union of Basic and Clinical Pharmacology (IUPHAR) would like to ...
Mario Landys Chovel Cuervo, Silvio Perea
doaj  

Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment [PDF]

, 2018
Eptacog alfa (NovoSeven®) is a vitamin K-dependent recombinant Factor VIIa produced by genetic engineering from baby hamster kidney (BHK) cells as a single peptide chain of 406 residues. After activation, it consists of a light chain (LC) of 152 amino
Eravci, Murat, Hinderlich, Stephan, Mahboudi, Fereidoun, Montacir, Houda, Montacir, Othman, Parr, Maria Kristina, Saadati, Amirhossein, Springer, Andreas   +7 more
core   +2 more sources

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

Bioethical issues in the development of biopharmaceuticals [PDF]

, 2012
Development of biopharmaceuticals is a challenging issue in bioethics. Unlike conventional, small molecular weight drugs, biopharmaceuticals are proteins derived from DNA technology and hybrid techniques with complex three dimensional structures ...
Protić Dragana, Todorović Zoran
core   +1 more source

Model‐Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 322-335, February 2026.
Model‐informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHI) inhibitor aimed at treating anemia in chronic kidney disease patients.
Kelly M. Mahar, Shuying Yang, Brendan Johnson, Sandra A.G. Visser, Paul van den Berg, Martijn van Noort, Teun M. Post   +6 more
wiley   +1 more source

Sovereign Immunity for Rent: How the Commodification of Tribal Sovereign Immunity Reflects the Failures of the U.S. Patent System [PDF]

, 2019
Last year, a Fortune 500 pharmaceutical company attempted to rent the sovereign immunity of an American Indian tribe in order to shield its patents on a dry-eye drug from invalidation by generic competitors in inter partes review.
Geddes, Katrina G
core   +1 more source

The process defines the product: what really matters in biosimilar design and production? [PDF]

, 2017
Biologic drugs are highly complex molecules produced by living cells through a multistep manufacturing process. The key characteristics of these molecules, known as critical quality attributes (CQAs), can vary based on post-translational modifications ...
Jaquez, O.A. (Orlando A.), Vulto, A.G. (Arnold)   +1 more
core   +4 more sources

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

The Portuguese Society of Rheumatology position paper on the use of biosimilars [PDF]

, 2014
Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious ...
Aguiar, R, Ambrósio, C, André, R, Araújo, F, Barcelos, F, Bernardes, M, Bogas, M, Canhão, H, Castelão, W, Coelho, PC, Cordeiro, I, Costa, L, Cunha, I, Duarte, C, Faustino, A, Fernandes, S, Fonseca, JE, Garcês, S, Gonçalves, J, Las, V, Leitão, R, Malcata, A, Maurício, L, Meirinhos, T, Melo-Gomes, JA, Miguel, C, Miranda, LC, Monteiro, P, Neto, A, Pereira da Silva, JA, Pimenta, S, Pimentel-Santos, FM, Pimentão, JB, Ramiro, Sofia, Ramos, JC, Roxo, Ana, Santos, H, Sepriano, A, Silva, C, Silva, M, Tavares, V, Teixeira, F   +41 more
core